## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($133.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. 3 Top Value Stocks to Buy and Hold for 2026**
- Source: Morningstar | 20251223T130958 | Bullish | Relevance: 96%
- This article identifies three top value stocks—Campbell's (CPB), Bristol-Myers Squibb (BMY), and Constellation Brands (STZ)—that Morningstar believes are attractive long-term investments for 2026. These companies share characteristics such as being on the value side of the Morningstar Style Box, appearing on Morningstar’s Best Companies to Own list, possessing wide economic moats, predictable cash flows, and strong management. Each company is highlighted for specific reasons that make its stock currently undervalued despite potential challenges.

**2. Diageo plc $DEO Shares Sold by Roffman Miller Associates Inc. PA**
- Source: MarketBeat | 20251223T121017 | Somewhat-Bullish | Relevance: 69%
- Roffman Miller Associates Inc. PA reduced its stake in Diageo plc by 15.1% in Q3, selling 13,799 shares. Despite this, other institutions significantly increased their holdings, with Arrowstreet Capital notably adding 559,547 shares. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $119, while the stock currently trades around $86.79.

**3. Ambev inks deal to use AB InBev’s BEES B2B commerce platform**
- Source: Digital Commerce 360 | 20251224T140940 | Neutral | Relevance: 64%
- Ambev S.A. has formalized an agreement with its controlling shareholder, Anheuser‑Busch InBev, to continue utilizing and operating the BEES B2B digital commerce platform. This platform is integral for managing orders from retailers and small businesses across Ambev's markets, shifting customer ordering from manual processes to a digital, self-service model. Ambev will pay annual fees for access, with pricing benchmarked against similar digital commerce agreements, and the deal includes provisions for Ambev to participate economically if a third party acquires an interest in the entity owning BEES.

**4. Wheaton Precious Metals stock hits all-time high at 121.43 USD**
- Source: Investing.com | 20251222T151017 | Somewhat-Bullish | Relevance: 63%
- Wheaton Precious Metals Corp (NYSE: WPM) stock reached an all-time high of $121.43, now trading at $122.81, reflecting over 108% growth in the past year. Despite slightly missing Q3 2025 analyst expectations for EPS and revenue, investor sentiment remains positive, bolstered by a significant gold stream agreement and an "Outperform" rating upgrade from RBC Capital. The company's strong financial health, with an 84.25% gross profit margin and 50.33% revenue growth, underpins this performance, though InvestingPro notes it is currently trading above its Fair Value.

**5. Mbx Biosciences stock hits all-time high of 34.85 USD**
- Source: Investing.com | 20251223T120840 | Somewhat-Bullish | Relevance: 63%
- MBX Biosciences (MBX) stock reached an all-time high of $34.85, reflecting a 49.41% increase over the past year and a 212.32% surge over six months. Despite trading slightly above its Fair Value, the company demonstrates financial stability with a strong balance sheet and a $1.37 billion market capitalization. Analysts offer varied outlooks, with price targets ranging from $18 to $80, following positive Phase 2 trial results for its lead drug candidate, canvuparatide.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Jefferies | $154 | $170 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Jefferies | down | Hold |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Long-term trend broken: trading 12.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $24.5B |
| Beta | 0.46 |
| 52W Range | $126.45 - $228.89 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 11.3 |
| Current P/E | 12.2 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.5% to -2.4% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram bearish (-0.58), momentum weakening. RSI neutral at 52. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.39% (CS: 18) | Weak |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | -0.58 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 0.875x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $140.33
- **Stop Loss:** $133.09 (5.2% risk)
- **Target:** $147.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 82
- **Position Value:** $11,507.06
- **Portfolio %:** 11.51%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*